Priming with a “simplified regimen” of HIV-1 DNA vaccine is as good as a “standard regimen” when boosted with heterologous HIV-1 MVA vaccine
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1742-4690
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Priming with a “simplified regimen” of HIV-1 DNA vaccine is as good as a “standard regimen” when boosted with heterologous HIV-1 MVA vaccine ; volume:9 ; number:2 ; day:13 ; month:9 ; year:2012 ; pages:1-2 ; date:9.2012
Retrovirology ; 9, Heft 2 (13.9.2012), 1-2, 9.2012
- Urheber
-
Munseri, P.
- Beteiligte Personen und Organisationen
-
Kroidl, A.
Nilsson, C.
Moshiro, C.
Aboud, S.
Joachim, A.
Geldmacher, C.
Aris, E.
Buma, D.
Lyamuya, E.
Gotch, F.
Godoy-Ramirez, K.
Pallangyo, K.
Maboko, L.
Marovich, M.
Robb, M.
Hoelscher, M.
Janabi, M.
Mann, P.
Joseph, S.
Mfinanga, S.
Stoehr, W.
Mhalu, F.
Wahren, B.
Biberfeld, G.
McCormack, S.
Sandstrom, E.
Bakari, M.
SpringerLink (Online service)
- DOI
-
10.1186/1742-4690-9-S2-P108
- URN
-
urn:nbn:de:1111-2016080725828
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Munseri, P.
- Kroidl, A.
- Nilsson, C.
- Moshiro, C.
- Aboud, S.
- Joachim, A.
- Geldmacher, C.
- Aris, E.
- Buma, D.
- Lyamuya, E.
- Gotch, F.
- Godoy-Ramirez, K.
- Pallangyo, K.
- Maboko, L.
- Marovich, M.
- Robb, M.
- Hoelscher, M.
- Janabi, M.
- Mann, P.
- Joseph, S.
- Mfinanga, S.
- Stoehr, W.
- Mhalu, F.
- Wahren, B.
- Biberfeld, G.
- McCormack, S.
- Sandstrom, E.
- Bakari, M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
HIV prevention by vaccine
Potency of an HIV-SAM™ vaccine in a heterologous prime-boost vaccination regimen
Stable HIV-1 envelope glycoprotein immune complexes as vaccine immunogens
P19-30. GTU® as beneficial HIV DNA vaccine vector system
Prospecting for an HIV vaccine
HIV vaccine research in Canada
Nanoparticles for HIV-1 vaccine delivery
HIV-1 vaccine immunogen design strategies
Is an HIV vaccine achievable? - Pros
New HIV peptide-based immunoassay resolves vaccine-induced seropositivity in HIV vaccine (Phase III) trial participants
Polyfunctional Calcium Phosphate Nanoparticles as a Novel Vaccine Platform against HIV-1
Preclinical Development of a Fusion Peptide Conjugate as an HIV Vaccine Immunogen
HIV prevention by vaccine
Potency of an HIV-SAM™ vaccine in a heterologous prime-boost vaccination regimen
Stable HIV-1 envelope glycoprotein immune complexes as vaccine immunogens
P19-30. GTU® as beneficial HIV DNA vaccine vector system
Prospecting for an HIV vaccine
HIV vaccine research in Canada
Nanoparticles for HIV-1 vaccine delivery
HIV-1 vaccine immunogen design strategies
Is an HIV vaccine achievable? - Pros
New HIV peptide-based immunoassay resolves vaccine-induced seropositivity in HIV vaccine (Phase III) trial participants
Polyfunctional Calcium Phosphate Nanoparticles as a Novel Vaccine Platform against HIV-1
Preclinical Development of a Fusion Peptide Conjugate as an HIV Vaccine Immunogen
HIV prevention by vaccine
Potency of an HIV-SAM™ vaccine in a heterologous prime-boost vaccination regimen
Stable HIV-1 envelope glycoprotein immune complexes as vaccine immunogens
P19-30. GTU® as beneficial HIV DNA vaccine vector system
Prospecting for an HIV vaccine
HIV vaccine research in Canada
Nanoparticles for HIV-1 vaccine delivery
HIV-1 vaccine immunogen design strategies
Is an HIV vaccine achievable? - Pros
New HIV peptide-based immunoassay resolves vaccine-induced seropositivity in HIV vaccine (Phase III) trial participants
Polyfunctional Calcium Phosphate Nanoparticles as a Novel Vaccine Platform against HIV-1